Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEOMETRY-E: capmatinib + osimertinib versus platinum-pemetrexed chemotherapy in EGFR-mutant, T790M-negative, MET-amplified advanced NSCLC
MOH_2021-08-30_010228Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capmatinib and osimertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Novartis. Started Jul 2021; status: completed.
02
Drugs
capmatinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2021-08-30_010228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-30_010228.